Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 8Prostatic Neoplasms 2Neoplasms 2Multiple Myeloma 2HER2-positive Breast Cancer 2Endometrial Neoplasms 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Hematologic Neoplasms 1HR+/HER2+ Early Breast Cancer 1Glioma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Specimen Handling 3Biopsy 3X-Rays 2Standard of Care 2Practice Guidelines as Topic 2Interviews as Topic 2trastuzumab biosimilar HLX02 1pertuzumab 1erdafitinib 1copanlisib 1Trastuzumab 1Palliative Care 1PF-05280014 1Ontruzant 1Ogivri 1Methods 1Magnetic Resonance Spectroscopy 1Health Promotion 1Educational Status 1Early Intervention, Educational 1CT-P6 12C4 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant Solid Neoplasm × pertuzumab × 30 days × Clear all
NCT06136897 2026-05-29

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡